

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.*

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

COMPLETION OF CONNECTED TRANSACTION IN RELATION TO CAPITAL INCREASE IN PHARMARON NINGBO BIOLOGICS

References are made to the overseas regulatory announcement dated November 30, 2022 and the announcements dated March 30, 2023 and April 10, 2023 of Pharmaron Beijing Co., Ltd.* (the “**Company**”) respectively (collectively, the “**Capital Increase Announcements**”), in relation to the capital increase in Pharmaron (Ningbo) Biologics Co., Ltd. (康龍化成(寧波)生物醫藥有限公司) (“**Pharmaron Ningbo Biologics**”) (the “**Capital Increase**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Capital Increase Announcements.

The Board is pleased to announce that all of the condition precedents under the Capital Increase Agreement have been satisfied, and the payments of RMB which were to be made by all of the Relevant Investors (excluding HJ Partners), and the payment of USD which was to be made by HJ Partners were conducted on May 5, 2023 and September 19, 2023, respectively. Pharmaron Ningbo Biologics has also completed the relevant registration procedures with the relevant market supervision authorities and obtained an updated business license. Therefore, the Capital Increase was completed. The final consideration of the Capital Increase was approximately RMB950 million. Upon completion of the Capital Increase, Pharmaron Ningbo Biologics has become a non-wholly owned subsidiary of the Company and the financial results of Pharmaron Ningbo Biologics will remain to be consolidated into the Company’s financial results.

Immediately following the completion of the Capital Increase, the shareholding structure of Pharmaron Ningbo Biologics is as follows:

Shareholder	Registered Capital (RMB)	Shareholding percentage
The Company	3,100,000,000	88.8915%
Kangjun Zhongyuan	76,684,211	2.1989%
Kangjun Investment	4,894,737	0.1404%
Suzhou Gao Ling Qirui	40,789,474	1.1696%
Zhuhai Xingbo	40,789,474	1.1696%
Yongxin Phoenix	40,789,474	1.1696%
Ningbo Shangchuang	20,394,737	0.5848%
Mr. Yu Yuejiang	44,868,421	1.2866%
HJ Partners	36,615,732	1.0499%
Zhangkeherun	20,394,737	0.5848%
Huimei Jiankang	20,394,737	0.5848%
Dongzheng Mingde	8,157,895	0.2339%
Dongzheng Hechuang	8,157,895	0.2339%
Hongfeng Venture	8,157,895	0.2339%
C&D Emerging	8,157,895	0.2339%
Jiaxing Jingtai	8,157,895	0.2339%
Total	<u>3,487,405,209</u>	<u>100%</u>

Note: The above figures were subject to rounding adjustments as requested by the relevant market supervision authorities.

By order of the Board
Pharmaron Beijing Co., Ltd.*
 康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
 September 20, 2023

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as nonexecutive Directors; Mr. Zhou Qilin, Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

* For identification purposes only